Fig. 4: Impact of CMV viremia on CVID patients γδ T cells.

PBMCs from healthy CMV seronegative individuals (CMV⁻), healthy seropositive individuals (CMV⁺), CVID patients, and CMV/CVID patients were analyzed by flow cytometry (see gating strategy in Supplementary Fig. 1). Graphs show (a) total γδ T cells counts (n = 11 CMV⁻, 9 CMV⁺, 12 CVID and 5 CMV/CVID), (b) Vδ1⁺, Vδ2⁺ and Vδ1⁻/Vδ2⁻ subsets as a frequency of total CD3⁺ T cells (n = 19 CMV⁻, 15 CMV⁺, 18 CVID and 5 CMV/CVID) ****P < 0.0001, and (c) ratio of Vδ1/Vδ2 (n = 21 CMV⁻, 14 CMV⁺, 18 CVID and 5 CMV/CVID) ****P < 0.0001. d Graph and plots show coreceptor (CD4/CD8) expression by Vδ1⁺ subset (n = 13 CMV⁻, 14 CMV⁺, 19 CVID and 5 CMV/CVID), where *P < 0.05 **P < 0.01 ***P < 0.001 ****P < 0.0001 (exact P values provided in source data file). e Graph showing Vδ1⁺ and Vδ2⁺ subset frequencies separated based on no genetic diagnosis for CVID (n = 15) and genetic diagnosis for CVID (n = 3) and CMV/CVID (n = 4) cohorts, where *P = 0.033, **P = 0.004, ***P = 0.0006. For those with genetic diagnosis, symbol shape indicates specific gene implicated. For all graphs, each point represents an individual. For box and whisker graphs, line is at median, box is upper and lower quartiles, and error bars are minimum and maximum values. Statistical significance was calculated using either one-way ANOVA with Holm-Sidak’s multiple comparison test with single pooled variance or two-way ANOVA with Sidak’s multiple comparison test with single pooled variance. NFKB1 nuclear factor kappa B subunit 1 gene, NFKB2 nuclear factor kappa B subunit 2 gene, TCF3 transcription factor 3 gene.